NeuroPace, Inc. (NASDAQ:NPCE) Insider Sells $48,032.00 in Stock

NeuroPace, Inc. (NASDAQ:NPCE) insider Martha Morrell sold 3,200 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $15.01, for a total value of $48,032.00. Following the completion of the sale, the insider now directly owns 87,062 shares of the company’s stock, valued at $1,306,800.62. The trade was a 3.55 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $14.19 on Friday. The stock has a market cap of $423.57 million, a price-to-earnings ratio of -14.19 and a beta of 2.02. NeuroPace, Inc. has a 12 month low of $5.45 and a 12 month high of $18.15. The stock’s 50 day moving average price is $11.75 and its 200 day moving average price is $8.81. The company has a debt-to-equity ratio of 6.03, a current ratio of 5.59 and a quick ratio of 4.77.

NeuroPace (NASDAQ:NPCE) last announced its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.26) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The company had revenue of $21.06 million for the quarter, compared to the consensus estimate of $19.33 million. During the same period in the previous year, the business earned ($0.28) EPS. Equities research analysts anticipate that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on NPCE shares. UBS Group started coverage on NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 price target on the stock. Wells Fargo & Company boosted their target price on NeuroPace from $13.00 to $17.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, JPMorgan Chase & Co. upped their price target on NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a report on Tuesday, December 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $14.80.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Palumbo Wealth Management LLC bought a new stake in NeuroPace during the fourth quarter worth about $129,000. Financial Advocates Investment Management boosted its stake in NeuroPace by 27.8% in the fourth quarter. Financial Advocates Investment Management now owns 23,000 shares of the company’s stock valued at $257,000 after acquiring an additional 5,000 shares during the last quarter. KCK LTD. bought a new position in NeuroPace in the fourth quarter valued at approximately $58,981,000. JPMorgan Chase & Co. raised its holdings in NeuroPace by 106.3% in the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after purchasing an additional 6,181 shares during the period. Finally, Barclays PLC raised its holdings in NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock worth $144,000 after purchasing an additional 16,007 shares during the period. Institutional investors and hedge funds own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.